4 240

Cited 31 times in

Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization

Authors
 Hae Min Kang  ;  Hyoung Jun Koh 
Citation
 AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.155(4) : 713-719, 2013 
Journal Title
 AMERICAN JOURNAL OF OPHTHALMOLOGY 
ISSN
 0002-9394 
Issue Date
2013
MeSH
Adult ; Angiogenesis Inhibitors/therapeutic use* ; Antibodies, Monoclonal, Humanized/therapeutic use ; Bevacizumab ; Choroidal Neovascularization/drug therapy* ; Choroidal Neovascularization/physiopathology ; Coloring Agents ; Female ; Fluorescein Angiography ; Humans ; Indocyanine Green ; Intravitreal Injections ; Male ; Middle Aged ; Photochemotherapy* ; Photosensitizing Agents/therapeutic use ; Porphyrins/therapeutic use ; Ranibizumab ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors* ; Visual Acuity/physiology ; Young Adult
Keywords
Adult ; Angiogenesis Inhibitors/therapeutic use* ; Antibodies, Monoclonal, Humanized/therapeutic use ; Bevacizumab ; Choroidal Neovascularization/drug therapy* ; Choroidal Neovascularization/physiopathology ; Coloring Agents ; Female ; Fluorescein Angiography ; Humans ; Indocyanine Green ; Intravitreal Injections ; Male ; Middle Aged ; Photochemotherapy* ; Photosensitizing Agents/therapeutic use ; Porphyrins/therapeutic use ; Ranibizumab ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors* ; Visual Acuity/physiology ; Young Adult
Abstract
PURPOSE: To compare visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) injection or photodynamic therapy (PDT) for idiopathic choroidal neovascularization (CNV). DESIGN: Retrospective study. METHODS: Among 29 eyes (28 patients), 15 eyes (15 patients) received anti-VEGF therapy and 14 eyes (13 patients) received PDT. Best-corrected visual acuity (BCVA, logMAR [logarithm of minimal angle of resolution]) at baseline and 1, 3, 6, 12, and 24 months after initial treatment were compared. The eyes were classified by BCVA changes: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: Mean BCVA was 0.56 ± 0.38 logMAR (20/72 in Snellen equivalent) in the PDT group and 0.44 ± 0.59 logMAR (20/55 in Snellen equivalent) in the anti-VEGF group at baseline (P = .104, Mann-Whitney U test). The anti-VEGF group showed significantly better mean BCVA at each follow-up visit when compared with that of PDT (P = .004 at 1 month, P = .002 at 3 months, P = .037 at 6 months, P = .031 at 12 months, and P = .049 at 24 months; Mann-Whitney U test, respectively). When compared with the baseline, mean BCVA at each follow-up visit was better in the anti-VEGF group (P = .196 at 1 month, P = .007 at 3 months, P = .046 at 6 months, P = .046 at 12 months, and P = .049 at 24 months; Wilcoxon signed rank test, respectively), whereas BCVA in the PDT group was not. At 24 months, all eyes (100.0%) treated with anti-VEGF showed stable or improved BCVA, whereas 3 eyes (21.3%) showed visual deterioration after PDT. CONCLUSIONS: Anti-VEGF therapy was superior to PDT for idiopathic CNV, and superior efficacy was sustained until 24 months.
Full Text
http://www.sciencedirect.com/science/article/pii/S0002939412007209
DOI
10.1016/j.ajo.2012.10.010
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Hae Min(강혜민)
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86571
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse